Publication date: Feb 11, 2020
Liquid biopsies are still far from widely implanted in the clinical arena. Issues related to the added sensitivity of this test beyond conventional methods have not been fully resolved. Additionally, issues related to the specificity of these results especially as many cancers may share common mutation need further investigations. One way to resolve this may include the development and testing of large gene panels to add higher specificity. On the other hand, further studies are needed to support the idea that ctDNA or circulating tumor cells may constitute a better representation of the tumor subpopulation that is capable of metastasizing, which will strongly support its clinical value. Finally, survival studies showing a positive impact of this technology will also justify its widespread implementation in clinical practice.
Alrabadi, N., Haddad, R., and Alomari, A.K. Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives. 25784. 2020 Curr Treat Options Oncol (21):3.
|disease||MESH||circulating tumor cells|
- Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer.
- Novel Genetic Variants of ALG6 and GALNTL4 of the Glycosylation Pathway Predict Cutaneous Melanoma-Specific Survival.
- An ultrasensitive colorimetric test for the detection of somatic rare mutations in DNA.